

ASX Announcement

4 June 2024

## ENTITLEMENT OFFER CLEANSING NOTICE

Genetic Signatures Limited ACN 095 913 205 (ASX: GSS, the “Company”) gives notice under section 708AA(2)(f) of the Corporations Act 2001 (Cth) (“Corporations Act”), as modified by the Australian Securities and Investments Commission Corporations (Non-Traditional Rights Issues) Instrument 2016/84 and ASIC Corporations (Disregarding Technical Relief) Instrument 2016/73 (“ASIC Instruments”). Where applicable, references in this notice to sections of the Corporations Act are to those sections as modified by the ASIC Instruments.

The Company today announced a placement to institutional investors of new fully paid ordinary shares in the Company (“New Shares”) (“Placement”) to raise up to approximately A\$6 million and a fully underwritten accelerated non-renounceable pro-rata entitlement offer of 32,048,564 New Shares in the Company (subject to rounding of entitlements) to raise approximately A\$24 million (“Entitlement Offer” and, together with the Placement, the “Offer”).

Under the Entitlement Offer, eligible shareholders of the Company will be entitled to subscribe for 1 New Share for every 5.82 ordinary shares they hold in the Company as at 7.00pm (Sydney, Australia time) on the record date, being Thursday, 6 June 2024. Each New Share issued under the Entitlement Offer will be issued at an issue price of A\$0.75. The Entitlement Offer consists of an institutional component, to be conducted over the next two days and a retail component, which will be open from Wednesday, 12 June 2024 to Monday, 1 July 2024, unless extended or withdrawn.

With respect to the Entitlement Offer, the Company advises that:

- (a) the New Shares will be offered for issue without disclosure to investors under Part 6D.2 of the Corporations Act;
- (b) this notice is being given under section 708AA(2)(f) of the Corporations Act;
- (c) as at the date of this notice, the Company has complied with:
  - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - (ii) sections 674 and 674A of the Corporations Act;
- (d) as at the date of this notice, there is no excluded information of the type referred to in sections 708AA(8) and 708AA(9) of the Corporations Act; and

- (e) the potential effect of the issue of New Shares on the control of the Company and the consequences of that effect will depend on a number of factors, including investor demand, existing shareholdings in the Company and the extent to which eligible shareholders take up New Shares under the Entitlement Offer. However, having regard to the terms of the Entitlement Offer which is structured as a pro rata issue, the underwriting and sub-underwriting arrangements for the Entitlement Offer and the nature of the underwriters and sub-underwriters, at this time, the Company does not expect that any person will increase their percentage shareholding in the Company in a way which will have a material impact on the control of the Company.

In addition to paragraph (e) above:

- given the structure of the Entitlement Offer as a pro rata offer, if all Eligible Shareholders take up their full entitlements under the Entitlement Offer, they will maintain their existing percentage interest in the total issued share capital of the Company in so far as the Entitlement Offer is concerned. However as set out above, in addition to the Entitlement Offer, the Company will undertake the Placement. The Placement will involve the issue of approximately an additional 8 million fully paid ordinary shares ("Placement Shares"). The Placement Shares will represent approximately 3.5% of the fully paid ordinary shares on issue in the Company following completion of both the Placement and the Entitlement Offer. Accordingly, existing shareholders of the Company will be diluted because of the Placement, even if they take up their full Entitlement under the Entitlement Offer. The board of directors of the Company does not consider that the Placement will have any material impact on the control of the Company.
- if Eligible Shareholders do not take up all of their entitlements in the Entitlement Offer, their holdings are likely to be diluted;
- the proportional interests of Shareholders who are ineligible shareholders will be diluted because those Shareholders are not entitled to participate in the Entitlement Offer; and
- the Entitlement Offer is fully underwritten by Bell Potter Securities Limited (ACN 006 390 772) and Taylor Collison Limited (ABN 53 008 172 450) ("Joint Underwriters") pursuant to an underwriting agreement between the Company and the Joint Underwriters. In the event there is a shortfall under the Entitlement Offer, those shortfall shares will be allocated to the Joint Underwriters and sub-underwriters. The issue of New Shares to the Joint Underwriters (or any sub-underwriters appointed by the Joint Underwriters) is not expected to have any material effect on the control of the Company.

– ENDS –

### Authorisation and Additional Information

This announcement was authorised by the Board of Directors of Genetic Signatures Limited.

For further information, see our website ([www.geneticsignatures.com](http://www.geneticsignatures.com)) or contact us as below:

**Dr Neil Gunn**  
Director and  
Interim Chief Executive Officer  
[neil.gunn@geneticsignatures.com](mailto:neil.gunn@geneticsignatures.com)  
T: +61 (0)2 9870 7580

**Karl Pechmann**  
Chief Financial and Operating Officer  
and Company Secretary  
[karl.pechmann@geneticsignatures.com](mailto:karl.pechmann@geneticsignatures.com)

**About Genetic Signatures Limited:** Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base®**. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen™* brand. Genetic Signatures' proprietary MDx **3base®** platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospitals and pathology laboratories undertaking infectious disease screening. Genetic Signatures is leveraging strong COVID-19 related sales of its *EasyScreen™* respiratory kits and the growing interest in its gastroenteritis products to further commercialise its **3base®** technology to rapidly and cost effectively screen for a wide array of infectious pathogens including antibiotic resistant bacteria, sexually transmitted infections, meningitis and mosquito borne viral diseases.